@article{59a1eb6108ea4915a4d4f7af00e1f9ca,
title = "Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010)",
abstract = "BACKGROUND: Parkinson's disease (PD)-associated psychosis is a well-known non-motor complication, occurring years after diagnosis of PD. Incidence data vary across different studies highlighting a need for long-term observation and clinical definition. OBJECTIVE: To determine the incidence of psychosis in patients with PD and to investigate their survival in an incident cohort study from 1991-2010 in Olmsted County, MN. METHODS: We used the Rochester Epidemiology Project to define an incident-cohort study of parkinsonism (1991-2010) in Olmsted County, MN. A movement-disorder specialist reviewed the electronic medical records and applied diagnosis criteria to PD. Psychosis was diagnosed using of NINDS/NIMH unified criteria. RESULTS: We identified 669 cases of parkinsonism; 297 patients were clinically diagnosed with PD. 114/297 (38.4%) patients had evidence of psychosis (60% male); the median onset age of psychosis was 79.4 years. The incidence of Parkinson's disease psychosis (PDP) was 4.28/100 person-years. PDP patients had a 71% increased risk of death compared to PD patients. In PD patients without psychosis, men had 73.4% increased risk of death compared to women, whereas no significant sex difference was observed among PDP men vs. women. Of 114 patients diagnosed with psychosis, 59 were treated with antipsychotics. There was no significant difference in survival between treated and untreated patients. CONCLUSION: PDP increased the odds of death compared to PD patients. Men with PD without psychosis had greater odds of death compared to women; however, in PD with psychosis the odds of death were comparable among sexes. Lastly, treatment with anti-psychotics did not significantly affect survival.",
keywords = "Parkinsonism, antipsychotics, delirium, hallucinations, psychosis",
author = "Stang, {Cole D.} and Mullan, {Aidan F.} and Emanuele Camerucci and Mania Hajeb and Pierpaolo Turcano and Peter Martin and Mielke, {Michelle M.} and Josephs, {Keith A.} and Matthew Splett and Victor Abler and Boeve, {Bradley F.} and Bower, {James H.} and Rodolfo Savica",
note = "Funding Information: This study used the resources of the Rochester Epidemiology Project (REP) medical records-linkage system, which is supported by the National Institute on Aging (NIA; AG 058738), by the Mayo Clinic Research Committee, and by fees paid annually by REP users. The content of this article is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health (NIH) or the Mayo Clinic. Funding Information: Our results indicate that the overall incidence of PDP was 4.28 per 100 person-years and the prevalence was 38.4%. PDP patients had an increased risk of death compared to PD patients. Men with PD without psychosis had greater odds of death compared to women; on the other hand, in PD with psychosis the odds of death were comparable among men and women. However, there was not an increased risk of mortality in patients with unresolved psychosis compared to those who had resolution of their psychosis, and there was no difference in risk between treated and untreated PDP patients. Our results, if confirmed, highlight the importance of an early treatment of PDP and the need for more effective medications/treatment for PDP. The role of PDP in the physiopathology of PD needs to be further MMM reports consulting for Brain Protection and receiving research funding from the NIH and Biogen. KAJ reports research support from NIA and NINDS. JHB reports research support from Abb-Vie, Inc. BFB serves on the Advisory Board of the Tauopathy Consortium; has contracts with Axovant and GE Healthcare and grants from NIA, NINDS, the Mangurian Foundation, and the Little Family Foundation. RS receives research support from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Mayo Clinic Small Grants Program National Center for Advancing Translational Sciences (NCATS) and Acadia Pharmaceuticals Inc. The remaining authors have no conflicts of interest to report. Publisher Copyright: {\textcopyright} 2022 - IOS Press. All rights reserved.",
year = "2022",
doi = "10.3233/JPD-213035",
language = "English (US)",
volume = "12",
pages = "1319--1327",
journal = "Journal of Parkinson's disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "4",
}